Skip to main content

Table 1 Patient descriptive characteristics

From: Prevalence of postprandial hyperglycaemia in basal insulin-treated patients with type 2 diabetes mellitus with controlled fasting glycaemia and elevated glycosylated haemoglobin

Patients’ physical exploration
N = 98 Basal visit Final visit
Weight (kg) 82.2 (16.0) 81.8 (15.9)
Body mass index (BMI) (kg/m2) 30.0 (5.2) 29.8 (5.2)
Waist perimeter (WP) (cm) 101.3 (13.1) 102.2 (14.8)
Abdominal obesity
 According to IDF (WP > 80 cm women and > 90 cm men) 89 (90.8%) 88 (89.8%)
 According to GLESMO (WP > 88 cm women and > 94 cm men) 76 (77.6%) 78 (79.6%)
 According to NCEP-ATP III (WP > 88 cm women and > 102 cm men) 62 (63.3%) 62 (63.3%)
Fasting glycaemia (mg/dL) 107.7 (16.8)
HbA1c (%) 7.9 (0.6)
HbA1c (mmol/mol) 63 (6)
Oral antidiabetic drugs used
 Basal insulin dose (U/day) 31.6 (17) 31.6 (16.9)
  Any OAD 87 (88.8%) 89 (90.8%)
  Metformin 80 (81.6%) 81 (82.7%)
 Sulfonylureas 31 (31.6%) 31 (31.6%)
  DPP-4 inhibitor 30 (30.6%) 31 (31.6%)
  1. Data are presented as mean (SD) or n (%). AMI acute myocardial infarction, ALO acute lung oedema, OAD oral antidiabetic drug